Clopidogrel Tablet, Film Coated
Product Images NDC 50090-5868

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 50090-5868). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Clopidogrel Fig1)

A chart illustrating the effect of multiple doses of proton pump inhibitors (PPIs) on exposure to Clopidogrel active metabolite. It shows mean and 90% confidence intervals for active metabolite AUC relative to Clopidogrel bisulfate administered alone, across four PPIs: Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg. The horizontal axis measures change relative to Clopidogrel bisulfate alone from 0.4 to 1.4.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

A line graph showing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up, comparing Clopidogrel Bisulfate (+ aspirin) versus placebo (+ aspirin). The graph indicates lower cumulative event rates for Clopidogrel Bisulfate over time, with a statistical significance noted as P=0.00009.*

FDA Label Image

Figure-3 (Clopidogrel Fig3)

A data table presenting subgroup analyses comparing Clopidogrel Bisulfate 75 mg film-coated tablets versus placebo. It includes sample sizes, event numbers and percentages for subgroups by age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, previous stroke, Heparin/LMWH, Aspirin dosage, GPIIb/IIIa antagonist use, beta-blocker, and ACE inhibitor use. Hazard ratios with 95% confidence intervals are displayed graphically for each subgroup and overall outcomes.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

A line graph depicting the percentage of patients who died before first discharge over days since randomization (up to 28 days). It compares two groups: placebo with 8.1% deaths and clopidogrel with 7.5% deaths, indicating a 7% proportional risk reduction (p = 0.03).*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

A Kaplan-Meier curve graph depicting the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days since randomization. It compares outcomes between patients receiving Clopidogrel and placebo, showing a 9% proportional risk reduction with Clopidogrel (p=0.002). The y-axis shows the percentage with events, and the x-axis shows days since randomization.*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

A forest plot chart depicting the odds ratio (99% CI) comparing the effectiveness of Clopidogrel Bisulfate versus placebo across various subgroups including gender, age, hours since onset, systolic blood pressure, heart rate, and use of fibrinolytic agents. The chart presents the number of participants and percentage outcomes for each subgroup, showing which group favors Clopidogrel Bisulfate or placebo.*

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

A line graph showing cumulative event rates (%) of fatal or non-fatal vascular events over 36 months of follow-up for aspirin versus clopidogrel bisulfate. The graph illustrates that aspirin has a slightly higher cumulative event rate compared to clopidogrel bisulfate, with a p-value of 0.045 indicating statistical analysis of the difference.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

A forest plot chart comparing the hazard ratios with 95% confidence intervals for Clopidogrel Bisulfate versus Aspirin across qualifying conditions: Stroke, MI, PAD, and Overall. The chart includes sample sizes and event counts for each group, visually indicating whether outcomes favor Clopidogrel Bisulfate or Aspirin.*

FDA Label Image

Chemical Structure (Clopidogrel Str)

Chemical structure of Clopidogrel Bisulfate, showing its molecular arrangement with characteristic rings and functional groups including a thiophene ring and a bicyclic structure containing chlorine and ester groups.*

FDA Label Image

Label Image (Lbl500905868)

Clopidogrel 75 mg film-coated tablets label by A-S Medication Solutions. The label indicates each film-coated tablet contains 75 mg of clopidogrel bisulfate equivalent to 75 mg clopidogrel. It includes storage instructions to keep the product between 68 to 77 degrees Fahrenheit and protect from moisture. Package contains 90 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.